Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Human Health

Human HealthOur main goal is to develop new pharmaceuticals with high versatility were there are wide-spread medical needs.

Further reading »

Animal Health

Animal HealthAnimal Health develops and improves existing medical treatments focusing on oncology.

Further reading »

The Share

Latest News

Results from Oasmia’s Phase III study will be presented at ASCO

April 24 2015
Uppsala, Sweden – April 24, 2015. The pharmaceutical company Oasmia Pharmaceutical announced today that data from the recently completed Phase III study with Paclical® for treatment of ovarian cancer will be presented at the 2015 ASCO Annual Meeting in Chicago. The principal investigator of the study, Ignace Vergote, will perform the presentation.
Further reading »

Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation

April 20 2015
Uppsala, Sweden – April 20, 2015. Oasmia Pharmaceutical AB (“Oasmia”) announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health. Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization. Paclical is planned for launch in the second half of 2015.
Further reading »

Interim report for the period May 2014 – January 2015

March 5 2015
Increased focus on Docecal
Further reading »